机器人骶骨阴道固定术联合根治性子宫切除术的网片暴露与远期结局
本研究回顾性分析了2006年7月至2023年8月期间在同一三级转诊中心接受机器人骶骨阴道固定术(rSCP)联合根治性子宫切除术(rRH)的109例患者,其中36例为癌症指征,73例为非癌症指征。结果显示脱垂复发12例(癌症组1例,非癌症组11例),网片暴露8例(癌症组1例,非癌症组7例),在54例随访≥12个月且有无尿失禁数据的患者中,新发尿失禁4例(7.4%)。结论认为联合手术的脱垂复发、网片暴露和新发尿失禁发生率可接受,癌症与非癌症病例结局相当,但研究把握度不足以检测微小差异。
要点
- rSCP联合rRH的脱垂复发率、网片暴露率和新发尿失禁率在可接受范围内。
- 癌症与非癌症指征患者的结局相当,但研究把握度不足。
- 有临床指征时,rSCP可安全地整合入rRH手术中。
核心结论
- 联合rSCP-rRH的脱垂复发、网片暴露和新发尿失禁发生率可接受。
- 癌症与非癌症病例的结局相当,但研究把握度不足以检测微小差异。
- 有临床指征时,rSCP可安全地整合入rRH。
研究设计与样本
- 回顾性队列研究,纳入2006年7月至2023年8月在同一三级转诊中心接受同期rSCP和rRH的患者,共109例(癌症36例,非癌症73例)。
- 采用Kaplan-Meier分析按指征(癌症 vs 非癌症)分层估计脱垂复发和网片暴露的时间。
主要发现
- 脱垂复发共12例:癌症组1/36,非癌症组11/73。
- 网片暴露共8例:癌症组1/36,非癌症组7/73;其中5例接受手术修整。
- 每组各有1例患者在≥10年后需要术后修整手术。
- 在54例随访≥12个月且有无尿失禁数据的患者中,新发尿失禁4例(7.4%),其中癌症组3例,非癌症组1例。
- 无复发或网片暴露患者的中位随访时间为15个月(IQR 7.5-43)。
临床怎么用
- 对于有临床指征的患者,可考虑在rRH中同期行rSCP以预防或治疗盆腔器官脱垂。
- 术后需长期随访网片暴露和脱垂复发,尤其是非癌症指征患者。
- 应关注新发尿失禁,并在随访中评估 continence 状态。
局限性
- 回顾性研究设计。
- 研究把握度不足以检测癌症与非癌症组间的微小差异。
- 无复发或网片暴露患者的中位随访时间仅15个月,可能低估远期事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate prolapse recurrence, mesh exposure, and de novo incontinence following robotic sacrocolpopexy (rSCP) with radical hysterectomy (rRH) for cancer and non-cancer indications. METHODS: We conducted a retrospective cohort study of patients undergoing concurrent rSCP and rRH at a tertiary referral center, July 2006-August 2023. Outcomes included prolapse recurrence (≥ stage 2 by POP-Q or symptomatic recurrence), mesh exposure, and de novo urinary incontinence within 12 months. Kaplan-Meier analyses estimated time to prolapse recurrence and mesh exposure stratified by indication (cancer vs non-cancer). RESULTS: In total, 109 patients underwent rSCP with rRH (36 for cancer, 73 for non-cancer indications). Median follow-up among patients without recurrence or mesh exposure was 15 months (IQR 7.5-43). Prolapse recurrence occurred in 12 patients: 1/36 and 11/73 in the cancer and non-cancer cohorts, respectively. One patient in each group required postoperative revision surgery after ≥10 years. Mesh exposure occurred in 8 patients: 1/36 and 7/73 in the cancer and non-cancer cohorts, respectively; 5 patients underwent surgical revision. Among 54 patients with ≥12 months follow-up and available continence data, de novo incontinence developed in 4 (7.4%) patients (3 cancer, 1 non-cancer). CONCLUSION: Concomitant rSCP-rRH demonstrates acceptable rates of prolapse recurrence, mesh exposure, and de novo incontinence. Although underpowered to detect small differences, outcomes were comparable in cancer vs non-cancer cases. rSCP can safely be integrated in rRH when clinically indicated.
引用
- Kapoor J, Vertosick E, Zipkin J, et al. Mesh Exposure and Long-term Outcomes in Robotic Sacrocolpopexy With Concomitant Radical Hysterectomy. Urology. 2026. PMID: 42617879. doi:10.1016/j.urology.2026.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。